A new class of radiopharmaceuticals known as "antagonists" offered clinicians enhanced diagnostic options and proved superior to legacy agents for imaging neuroendocrine tumors.

Demand for molecular imaging is likely to grow in the coming years, but most trainees receive little exposure to the burgeoning opportunity during medical school.

The findings, published June 22 in JAMA Neurology, should help identify people at the greatest risk of developing the disease.

Bracco subsidiary Blue Earth Diagnostics and PETNET Solutions, part of Siemens Healthineers, announced the multi-year agreement last week.

The Beloit, Wisconsin-based firm, known for producing molybdenum-99, is working with Chicago's Monopar Therapeutics on the treatment to battle severe cases of the disease.

“Black lives matter. The need to speak out against racism, racial injustice and inherent bias compels each of us as leaders in our community to act,” Founder and CEO Greg Piefer said in a recent message to employees.

The St. Louis-based firm submitted a stand-alone Drug Master File with the U.S. Food and Drug Administration, along with an Active Substance Master File with the European Medicines Agency, for its germanium-68 agent.

Engaging in such thought patterns over a long period of time could raise an individual's chance of developing the brain disease, according to a new study.